Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.08 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (paneth cells) | 0.10 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 2 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 3356
Sealed predictions
- AICDA in dopamine neurons, braak-0.07 (p 0.849) → -0.03 (p 0.946)receipt 3363
Swarm cases
receipt 3363: AICDA in dopamine neurons, braak
- power
- full sample +0.04 (p 0.874, n 18), 95% CI -0.43 to +0.50. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.06 (p 0.807, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.04 (p 0.861, n 18). could be the mix.
- skeptic
- leave-one-out range -0.07 to +0.17, sign flips 5; without severely affected donors +0.04 (p 0.874, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for AICDA in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts